SavedAdd your journal

Journals / Experimental Biomedical Research / 2022 / Cilt: 5 - Sayı: 2

Clopidogrel versus ticagrelor in chronic kidney disease patients presenting with acute coronary syndrome: A retrospective evaluation

Fahrettin Katkat
Irfan Sahin
Serkan Karahan
Orhan Ince
Ertugrul Okuyan
Muzaffer Murat Degertekin
Pages
183–193
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Method: This was a single-center retrospective comparison of in-hospital and 1-year major advance cardiovascular events (MACE) in patients with ACS and reduced estimated glomerular filtration rate (eGFR

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To compare the efficacy and bleeding risk of clopidogrel versus ticagrelor in patients presenting with the acute coronary syndrome (ACS).
📊
Key Findings & Data:Aim: To compare the efficacy and bleeding risk of clopidogrel versus ticagrelor in patients presenting with the acute coronary syndrome (ACS).
💡
Conclusion & Impact:Method: This was a single-center retrospective comparison of in-hospital and 1-year major advance cardiovascular events (MACE) in patients with ACS and reduced estimated glomerular filtration rate (eGFR
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To compare the efficacy and bleeding risk of clopidogrel versus ticagrelor in patients presenting with the acute coronary syndrome (ACS). Method: This was a single-center retrospective comparison of in-hospital and 1-year major advance cardiovascular events (MACE) in patients with ACS and reduced estimated glomerular filtration rate (eGFR

🔖

Cite This Article

Katkat, F., Sahin, I., Karahan, S., Ince, O., Okuyan, E., Degertekin, M. M. (2022). Clopidogrel versus ticagrelor in chronic kidney disease patients presenting with acute coronary syndrome: A retrospective evaluation. Experimental Biomedical Research, Cilt: 5 - Sayı: 2, 183–193. https://ajindex.com/articles/512590

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. 1]Karahan S, Okuyan EJE, Science AM. Systemic Inflammatory Index and Platelet- to-Lymphocyte Ratio Predicted Mortality in patients with Acute Myocardial Infarction. Experimental and Applied Medical Science. 2021
  2. 2(2):146-53. [2]Ellis CJ, Gamble GD, Williams MJA, et al. All-Cause Mortality Following an Acute Coronary Syndrome: 12-Year Follow-Up of the Comprehensive 2002 New Zealand Acute Coronary Syndrome Audit. Heart Lung Circ. 2019
  3. 28(2):245-56. [3]Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST- Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016
  4. 134(10):e123-55. [4]Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003
  5. 107(23):2908-13. [5]Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010
  6. 375(9711):283-93. [6]Karahan S, Katkat F, Okuyan E. Markers for creatinine height after percutaneous coronary intervention in patients with normal renal function. Ann Clin Anal Med. 2021
  7. 12(4):367-71. [7]Serebruany VL, Tomek A, Pokov AN, Kim MH. Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner? Expert Rev Cardiovasc Ther. 2015
  8. 13(12):1333-44. [8]De Filippo O, D'Ascenzo F, Raposeiras- Roubin S, et al. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. Eur Heart J Cardiovasc Pharmacother. 2020
  9. 6(1):31-42. [9]Laine M, Lemesle G, Burtey S, et al. TicagRelor Or Clopidogrel in severe o